Cargando…

Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation

BACKGROUND: Oral anticoagulation (OAC) reduces the risk of thromboembolic events in patients with atrial fibrillation (AF); however, thromboembolism (TE) still can occur despite OAC. Factors associated with residual risk for stroke, systemic embolism, or transient ischemic attack events despite OAC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carlisle, Matthew A., Shrader, Peter, Fudim, Marat, Pieper, Karen S., Blanco, Rosalia G., Fonarow, Gregg C., Naccarelli, Gerald V., Gersh, Bernard J., Reiffel, James A., Kowey, Peter R., Steinberg, Benjamin A., Freeman, James V., Ezekowitz, Michael D., Singer, Daniel E., Allen, Larry A., Chan, Paul S., Pokorney, Sean D., Peterson, Eric D., Piccini, Jonathan P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795305/ https://www.ncbi.nlm.nih.gov/pubmed/36589908 http://dx.doi.org/10.1016/j.hroo.2022.09.018

Ejemplares similares

Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
por: Steinberg, Benjamin A., et al.
Publicado: (2018)

Heart rate is associated with progression of atrial fibrillation, independent of rhythm
por: Holmqvist, Fredrik, et al.
Publicado: (2015)

Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
por: Washam, Jeffrey B., et al.
Publicado: (2018)

Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry
por: Fudim, Marat, et al.
Publicado: (2018)

Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF)
por: Steinberg, Benjamin A, et al.
Publicado: (2015)

Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT‐AF Registry
por: Jackson, Larry R., et al.
Publicado: (2015)

Disease understanding in patients newly diagnosed with atrial fibrillation
por: Kaufman, Brystana G, et al.
Publicado: (2018)

Catheter Ablation of Atrial Fibrillation in U.S. Community Practice—Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
por: Holmqvist, Fredrik, et al.
Publicado: (2015)

Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation
por: Black‐Maier, Eric, et al.
Publicado: (2017)

Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
por: Jackson, Larry R., et al.
Publicado: (2018)

Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation)
por: Thomas, Kevin L., et al.
Publicado: (2017)

Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies
por: Thind, Munveer, et al.
Publicado: (2022)

Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
por: Steinberg, Benjamin A., et al.
Publicado: (2013)

Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
por: Steinberg, Benjamin A., et al.
Publicado: (2015)

Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA(2)DS(2)‐VASc Scores: Findings From the ORBIT‐AF I and II Registries
por: Jackson, Larry R., et al.
Publicado: (2018)

Comparison of Patient‐Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT‐AF Registry
por: Perino, Alexander C., et al.
Publicado: (2019)

Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF I) Registry
por: O'Brien, Emily C., et al.
Publicado: (2016)

Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials
por: Thind, Munveer, et al.
Publicado: (2020)

Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT‐AF Registry
por: Fosbol, Emil L., et al.
Publicado: (2013)

The Role of Dronedarone in the Treatment of Atrial Fibrillation/Flutter in the Aftermath of PALLAS
por: Naccarelli, Gerald V, et al.
Publicado: (2014)

Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD‐AF and ORBIT‐AF registries
por: Lim, Toon Wei, et al.
Publicado: (2023)

Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT‐AF
por: O'Brien, Emily C., et al.
Publicado: (2018)

AIM‐AF: A Physician Survey in the United States and Europe
por: Camm, A. John, et al.
Publicado: (2022)

Real-world utilization of the pill-in-the-pocket method for terminating episodes of atrial fibrillation: data from the multinational Antiarrhythmic Interventions for Managing Atrial Fibrillation (AIM-AF) survey
por: Reiffel, James A, et al.
Publicado: (2023)

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation
por: O'Brien, Emily C., et al.
Publicado: (2015)

Oral Anticoagulation and Antiarrhythmic Drug Therapy for Atrial Fibrillation
por: Reiffel, James A.
Publicado: (2018)

Oral Anticoagulant Therapy: When What Should Not Be Is and What Should Be Is Not
por: Reiffel, James A.
Publicado: (2019)

Going Beyond Antiarrhythmic–Anticoagulant Drug Interactions: Considerations in the Complex Medicated Patient
por: Reiffel, James A.
Publicado: (2019)

Considerations Regarding the Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation
por: Reiffel, James A.
Publicado: (2018)

Are we at the Goal Line with the Novel Oral Anticoagulants and Have We Reached the End of the Line for Dronedarone and Vernakalant – or is There More to Come?
por: Reiffel, James A
Publicado: (2014)

Neuromodulation for the Treatment of Heart Rhythm Disorders
por: Waldron, Nathan H., et al.
Publicado: (2019)

Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation
por: Maraj, Ilir, et al.
Publicado: (2018)

Cases of Azygous Coil Extraction
por: Sampognaro, James R., et al.
Publicado: (2021)

Editorial: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps
por: Reiffel, James A
Publicado: (2014)

TTR: Time in Therapeutic Range or “The Troublesome Report”?
por: Reiffel, James A.
Publicado: (2019)

Defining Drugs in the Electrophysiologist’s World
por: Reiffel, James A.
Publicado: (2017)

Adverse Events with Amiodarone—Will the List Ever End?
por: Reiffel, James A.
Publicado: (2018)

Time in the Therapeutic Range (TTR): An Overly Simplified Conundrum
por: Reiffel, James A.
Publicado: (2017)

When Silence Isn’t Golden: The Case of “Silent” Atrial Fibrillation
por: Reiffel, James A.
Publicado: (2017)

Reduced-dose Antiarrhythmic Drugs: Valuable or Valueless?
por: Reiffel, James A.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_brsktmr4uob1g2m4ebpdonth1a